BMO Capital analyst Juan C. Sanabria maintained a Buy rating on National Health Investors (NHI – Research Report) today and set a price target of $86.00.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Juan C. Sanabria has given his Buy rating due to a combination of factors including National Health Investors’ (NHI) strong financial performance and strategic initiatives. The company reported better-than-expected earnings for the first quarter of 2025, with notable growth in normalized funds available for distribution (FAD) and funds from operations (FFO), both exceeding market expectations. This positive financial performance is further supported by successful acquisition activities and continued deferral repayments, which have contributed to an upward revision in guidance.
Additionally, the company’s strategic moves, such as resetting rents at Discovery Senior Living and plans to release assets, indicate a proactive approach to optimizing its portfolio. Despite some challenges like seasonal occupancy declines, NHI’s ability to maintain and even raise its guidance reflects confidence in its operational strategies and future growth prospects. These factors collectively underpin Sanabria’s positive outlook and Buy rating for NHI’s stock.